Colorado 2025 Regular Session

Colorado House Bill HB1270 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1		First Regular Session
2	2		Seventy-fifth General Assembly
3	3		STATE OF COLORADO
4		-	~~REREVISED~~
5		-	This Version Includes All Amendments
6		-	~~Adopted~~ in the Second House
	4	+	REVISED
	5	+	This Version Includes All Amendments Adopted
	6	+	on Second Reading in the Second House
7	7		LLS NO. 25-0747.01 Brita Darling x2241
8	8		HOUSE BILL 25-1270
9	9		House Committees Senate Committees
10	10		Health & Human Services Health & Human Services
11	11		A BILL FOR AN ACT
12	12		C
13	13		ONCERNING GRANTING ELIGIBLE PATIENTS THE RIGHT TO TRY101
14	14		INDIVIDUALIZED INVESTIGATIONAL MEDICAL TREATMENTS .102
15	15		Bill Summary
16	16		(Note: This summary applies to this bill as introduced and does
17	17		not reflect any amendments that may be subsequently adopted. If this bill
18	18		passes third reading in the house of introduction, a bill summary that
19	19		applies to the reengrossed version of this bill will be available at
20	20		http://leg.colorado.gov
21	21		.)
22	22		The bill allows, but does not require, an eligible patient to request
23	23		from a manufacturer the manufacturer's individualized investigational
24	24		drug, biological product, or device, which is a drug, biological product,
25	25		or device that is unique and produced exclusively for use by an individual
26	26		patient based on the patient's own genetic profile. The manufacturer must
27	27		be operating within an institution that operates under federal rules for the
28	28		SENATE
29		-	3rd Reading Unamended
30		-	April 14, 2025
31		-	SENATE
32	29		2nd Reading Unamended
33	30		April 11, 2025
34	31		HOUSE
35	32		3rd Reading Unamended
36	33		March 14, 2025
37	34		HOUSE
38	35		2nd Reading Unamended
39	36		March 13, 2025
40	37		HOUSE SPONSORSHIP
41	38		Pugliese and Gilchrist, Bacon, Barron, Bird, Boesenecker, Bradley, Caldwell, Camacho,
42	39		Clifford, Duran, English, Espenoza, Feret, Froelich, Garcia, Garcia Sander, Gonzalez R.,
43	40		Hamrick, Jackson, Johnson, Keltie, Lieder, Lindsay, Marshall, Martinez, McCluskie,
44	41		McCormick, Rutinel, Stewart K., Story, Taggart, Titone, Weinberg, Winter T.
45	42		SENATE SPONSORSHIP
46		-	Kirkmeyer and Daugherty, Amabile, Bright, Catlin, Cutter, Frizell, Hinrichsen, Jodeh,
47		-	Kipp, Michaelson Jenet, Pelton B., Roberts, Simpson, Wallace
	43	+	Kirkmeyer and Daugherty,
48	44		Shading denotes HOUSE amendment. Double underlining denotes SENATE amendment.
49	45		Capital letters or bold & italic numbers indicate new material to be added to existing law.
50	46		Dashes through the words or numbers indicate deletions from existing law. protection of human subjects. An eligible patient is an individual who
51	47		has:
52	48		! A life-threatening or severely debilitating illness, as
53	49		attested to by the patient's treating physician;
54	50		! Considered all other treatment options currently approved
55	51		by the United States food and drug administration;
56	52		! Received a recommendation from the patient's treating
57	53		physician;
58	54		! Given written, informed consent for the use of the
59	55		individualized investigational drug, biological product, or
60	56		device; and
61	57		! Documentation from the treating physician that the
62	58		individual meets the definition of "eligible patient".
63	59		The bill authorizes, but does not require, a manufacturer to make
64	60		the individualized investigational drug, biological product, or device
65	61		available to an eligible patient at no charge, but the manufacturer may
66	62		require payment to cover the cost.
67	63		If any harm is caused to the eligible patient resulting from the use
68	64		of the individualized investigational drug, biological product, or device,
69	65		a private right of action cannot be brought against the manufacturer or
70	66		against any other individual or entity involved in the care of the eligible
71	67		patient with regard to the eligible patient's use of the individualized
72	68		investigational drug, biological product, or device, so long as the
73	69		manufacturer, individual, or entity complied with the law and exercised
74	70		reasonable care.
75	71		The bill prohibits any action against a health-care provider's
76	72		license based on the health-care provider's recommendations regarding
77	73		the use of the individualized investigational drug, biological product, or
78	74		device.
79	75		Nothing in the bill affects a health-care insurer's obligation under
80	76		current law relating to coverage for an insured's participation in a clinical
81	77		trial.
82	78		Be it enacted by the General Assembly of the State of Colorado:1
83	79		SECTION 1. In Colorado Revised Statutes, 25-45-102, amend2
84	80		(1) introductory portion and (2) as follows:3
85	81		25-45-102. Legislative declaration. (1) F
86	82		OR PURPOSES OF THIS4
87	83		PART 1, the general assembly finds and declares that:5
88	84		(2) It is the intent of the general assembly
89	85		FOR THIS PART 1 to6
90	86		allow for terminally ill patients to use potentially life-saving7
91	87		1270-2- investigational drugs, biological products, and devices.1
92	88		SECTION 2. In Colorado Revised Statutes, 25-45-103, amend2
93	89		the introductory portion as follows:3
94	90		25-45-103. Definitions. As used in this article PART 1, unless the4
95	91		context otherwise requires:5
96	92		SECTION 3. In Colorado Revised Statutes, 25-45-104, amend6
97	93		(1) and (3)(a) as follows:7
98	94		25-45-104. Drug manufacturers - availability of investigational8
99	95		drugs, biological products, or devices - costs - insurance coverage.9
100	96		(1) A manufacturer of an investigational drug, biological product, or10
101	97		device may make available the manufacturer's investigational drug,11
102	98		biological product, or device to eligible patients pursuant to this article12
103	99		PART 1. This article PART 1 does not require that a manufacturer make13
104	100		available an investigational drug, biological product, or device to an14
105	101		eligible patient.15
106	102		(3) (a) Nothing in this article PART 1 expands the coverage16
107	103		provided in sections SECTION 10-16-104 (20) or 10-16-104.6. C.R.S.17
108	104		SECTION 4. In Colorado Revised Statutes, amend 25-45-107 as18
109	105		follows:19
110	106		25-45-107. No cause of action created. This article PART 1 does20
111	107		not create a private cause of action against a manufacturer of an21
112	108		investigational drug, biological product, or device, or against any other22
113	109		person or entity involved in the care of an eligible patient using the23
114	110		investigational drug, biological product, or device, for any harm done to24
115	111		the eligible patient resulting from the investigational drug, biological25
116	112		product, or device, so long as the manufacturer or other person or entity26
117	113		is complying in good faith with the terms of this article PART 1, unless27
118	114		1270
119	115		-3- there was a failure to exercise reasonable care.1
120	116		SECTION 5. In Colorado Revised Statutes, add part 2 to article2
121	117		45 of title 25 as follows:3
122	118		PART 24
123	119		INDIVIDUALIZED TREATMENTS5
124	120		25-45-201. Legislative declaration. (1) F
125	121		OR PURPOSES OF THIS6
126	122		PART 2, THE GENERAL ASSEMBLY FINDS AND DETERMINES THAT :7
127	123		(a) S
128	124		OME PUBLIC AND PRIVATE ENTITIES OPERATING UNDER8
129	125		FEDERAL STANDARDS FOR THE PROTECTION OF HUMAN SUBJECTS IN9
130	126		RESEARCH DEVELOP INDIVIDUALIZED INVESTIGATIONAL DRUGS ,10
131	127		BIOLOGICAL PRODUCTS, AND DEVICES THAT ARE UNIQUE AND PRODUCED11
132	128		EXCLUSIVELY FOR USE BY AN INDIVIDUAL PATIENT BASED ON THE12
133	129		PATIENT'S GENETIC PROFILE, INCLUDING INDIVIDUAL GENE THERAPY ,13
134	130		ANTISENSE OLIGONUCLEOTIDES , AND INDIVIDUALIZED NEOANTIGEN14
135	131		VACCINES; AND15
136	132		(b) A
137	133		PATIENT WHO HAS A LIFE-THREATENING OR SEVERELY16
138	134		DEBILITATING ILLNESS MAY BENEFIT FROM THESE INDIVIDUALIZED17
139	135		TREATMENTS.18
140	136		(2) T
141	137		HEREFORE, THE GENERAL ASSEMBLY DECLARES THAT , IN19
142	138		ACCORDANCE WITH THE RECOMMENDATION OF THE PATIENT 'S TREATING20
143	139		PHYSICIAN AND WITH THE SAFEGUARDS DESCRIBED IN THIS PART 2, A21
144	140		PATIENT SHOULD HAVE THE RIGHT TO TRY AN INDIVIDUALIZED22
145	141		INVESTIGATIONAL DRUG, BIOLOGICAL PRODUCT, OR DEVICE, AND THE23
146	142		TREATING PHYSICIAN AND MANUFACTURER THAT PROVIDES THE24
147	143		INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR25
148	144		DEVICE, ACTING IN ACCORDANCE WITH THIS PART 2, SHOULD BE26
149	145		PROTECTED FROM ADVERSE CONSEQUENCES RESULTING FROM THE27
150	146		1270
151	147		-4- PATIENT'S DECISION TO TRY THE INDIVIDUALIZED INVESTIGATIONAL DRUG ,1
152	148		BIOLOGICAL PRODUCT, OR DEVICE.2
153	149		25-45-202. Definitions. A
154	150		S USED IN THIS PART 2, UNLESS THE3
155	151		CONTEXT OTHERWISE REQUIRES :4
156	152		(1) "E
157	153		LIGIBLE FACILITY" MEANS AN INSTITUTION OPERATING5
158	154		UNDER THE FEDERALWIDE ASSURANCE FOR THE PROTECTION OF HUMAN6
159	155		SUBJECTS IN ACCORDANCE WITH 45 CFR 46 AND 42 U.S.C. SEC. 289a.7
160	156		(2) "E
161	157		LIGIBLE PATIENT" MEANS AN INDIVIDUAL WHO HAS:8
162	158		(a) A
163	159		LIFE-THREATENING OR SEVERELY DEBILITATING ILLNESS , AS9
164	160		ATTESTED TO BY THE PATIENT'S TREATING PHYSICIAN;10
165	161		(b) I
166	162		N CONSULTATION WITH THE TREATING PHYSICIAN ,11
167	163		CONSIDERED ALL OTHER TREATMENT OPTIONS CURRENTLY APPROVED BY12
168	164		THE UNITED STATES FOOD AND DRUG ADMINISTRATION ;13
169	165		(c) R
170	166		ECEIVED A RECOMMENDATION FROM THE TREATING14
171	167		PHYSICIAN FOR USE OF AN INDIVIDUALIZED INVESTIGATIONAL DRUG ,15
172	168		BIOLOGICAL PRODUCT , OR DEVICE FOR TREATMENT OF THE16
173	169		LIFE-THREATENING OR SEVERELY DEBILITATING ILLNESS ;17
174	170		(d) G
175	171		IVEN WRITTEN, INFORMED CONSENT FOR THE USE OF THE18
176	172		INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR19
177	173		DEVICE, OR, IF THE PATIENT IS A MINOR OR LACKS THE MENTAL CAPACITY20
178	174		TO PROVIDE INFORMED CONSENT , A PARENT OR LEGAL GUARDIAN HAS21
179	175		GIVEN WRITTEN, INFORMED CONSENT ON THE PATIENT 'S BEHALF; AND22
180	176		(e) D
181	177		OCUMENTATION FROM THE TREATING PHYSICIAN THAT THE23
182	178		PATIENT MEETS THE REQUIREMENTS OF THIS SUBSECTION (2), INCLUDING24
183	179		ATTESTATION FROM THE TREATING PHYSICIAN THAT THE TREATING25
184	180		PHYSICIAN WAS CONSULTED IN THE CREATION OF THE WRITTEN , INFORMED26
185	181		CONSENT GIVEN UNDER THIS PART 2.27
186	182		1270
187	183		-5- (3) "INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL1
188	184		PRODUCT, OR DEVICE" MEANS A DRUG, BIOLOGICAL PRODUCT, OR DEVICE2
189	185		THAT IS UNIQUE AND PRODUCED EXCLUSIVELY FOR USE BY AN ELIGIBLE3
190	186		PATIENT, BASED ON THE PATIENT'S OWN GENETIC PROFILE, INCLUDING4
191	187		INDIVIDUALIZED GENE THERAPY , ANTISENSE OLIGONUCLEOTIDES , AND5
192	188		INDIVIDUALIZED NEOANTIGEN VACCINES .6
193	189		(4) "I
194	190		NSTITUTION" HAS THE MEANING SET FORTH IN 45 CFR 46.1027
195	191		(f).8
196	192		(5) "L
197	193		IFE-THREATENING OR SEVERELY DEBILITATING ILLNESS " HAS9
198	194		THE MEANING SET FORTH IN 21 CFR 312.81.10
199	195		(6) "M
200	196		INOR" MEANS AN INDIVIDUAL WHO IS UNDER EIGHTEEN11
201	197		YEARS OF AGE.12
202	198		(7) "W
203	199		RITTEN, INFORMED CONSENT " MEANS A WRITTEN13
204	200		DOCUMENT SIGNED BY AN ELIGIBLE PATIENT ; BY A PARENT OR LEGAL14
205	201		GUARDIAN, IF THE PATIENT IS A MINOR ; OR BY A DESIGNATED15
206	202		HEALTH-CARE AGENT PURSUANT TO A HEALTH -CARE POWER OF16
207	203		ATTORNEY, IF THE PATIENT IS INCAPACITATED, THAT, AT A MINIMUM:17
208	204		(a) E
209	205		XPLAINS THE CURRENTLY APPROVED PRODUCTS AND18
210	206		TREATMENTS FOR THE LIFE-THREATENING OR SEVERELY DEBILITATING19
211	207		ILLNESS FROM WHICH THE ELIGIBLE PATIENT SUFFERS ;20
212	208		(b) A
213	209		TTESTS THAT THE ELIGIBLE PATIENT CONCURS WITH THE21
214	210		TREATING PHYSICIAN'S BELIEF THAT ALL CURRENTLY APPROVED22
215	211		TREATMENTS ARE UNLIKELY TO PROLONG THE PATIENT 'S LIFE;23
216	212		(c) C
217	213		LEARLY IDENTIFIES THE SPECIFIC INDIVIDUALIZED24
218	214		INVESTIGATIONAL DRUG, BIOLOGICAL PRODUCT, OR DEVICE PROPOSED FOR25
219	215		TREATMENT OF THE ELIGIBLE PATIENT'S LIFE-THREATENING OR SEVERELY26
220	216		DEBILITATING ILLNESS;27
221	217		1270
222	218		-6- (d) DESCRIBES THE POTENTIAL BEST AND WORST OUTCOMES1
223	219		RESULTING FROM USE OF THE INDIVIDUALIZED INVESTIGATIONAL DRUG ,2
224	220		BIOLOGICAL PRODUCT, OR DEVICE, WITH A REALISTIC DESCRIPTION OF THE3
225	221		MOST LIKELY OUTCOME , INCLUDING THE POSSIBILITY THAT NEW ,4
226	222		UNANTICIPATED, DIFFERENT, OR WORSE SYMPTOMS MIGHT RESULT AND5
227	223		THAT DEATH COULD BE HASTENED BY THE PROPOSED TREATMENT , BASED6
228	224		ON THE PHYSICIAN'S KNOWLEDGE OF THE PROPOSED TREATMENT IN7
229	225		CONJUNCTION WITH AN AWARENESS OF THE ELIGIBLE PATIENT 'S8
230	226		CONDITION;9
231	227		(e) M
232	228		AKES CLEAR THAT THE PATIENT'S ELIGIBILITY FOR HOSPICE10
233	229		CARE MAY BE WITHDRAWN IF THE ELIGIBLE PATIENT BEGINS TREATMENT11
234	230		OF THE LIFE-THREATENING OR SEVERELY DEBILITATING ILLNESS WITH AN12
235	231		INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR13
236	232		DEVICE AND THAT HOSPICE CARE MAY BE REINSTATED IF SUCH TREATMENT14
237	233		ENDS AND THE PATIENT AGAIN MEETS HOSPICE CARE ELIGIBILITY15
238	234		REQUIREMENTS;16
239	235		(f) M
240	236		AKES CLEAR THAT IN-HOME HEALTH CARE MAY BE DENIED IF17
241	237		TREATMENT BEGINS;18
242	238		(g) M
243	239		AKES CLEAR THAT THE ELIGIBLE PATIENT 'S HEALTH19
244	240		INSURANCE PROVIDER OR HEALTH -CARE PROVIDER IS NOT OBLIGATED TO20
245	241		PAY FOR ANY CARE OR TREATMENTS CONSEQUENT TO THE USE OF THE21
246	242		INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR22
247	243		DEVICE UNLESS SPECIFICALLY REQUIRED BY LAW OR CONTRACT ;23
248	244		(h) S
249	245		TATES THAT THE PATIENT UNDERSTANDS THAT THEY ARE24
250	246		LIABLE FOR ALL EXPENSES CONSEQUENT TO THE USE OF THE25
251	247		INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR26
252	248		DEVICE, AND THAT THIS LIABILITY EXTENDS TO THE PATIENT 'S ESTATE,27
253	249		1270
254	250		-7- UNLESS A CONTRACT BETWEEN THE PATIENT AND THE MANUFACTURER OF1
255	251		THE INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR2
256	252		DEVICE STATES OTHERWISE; AND3
257	253		(i) S
258	254		TATES THAT THE ELIGIBLE PATIENT , OR, FOR AN ELIGIBLE4
259	255		PATIENT WHO IS A MINOR OR WHO LACKS CAPACITY TO PROVIDE INFORMED5
260	256		CONSENT, THE PARENT OR LEGAL GUARDIAN , CONSENTS TO THE USE OF6
261	257		THE INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR7
262	258		DEVICE FOR TREATMENT OF THE LIFE -THREATENING OR SEVERELY8
263	259		DEBILITATING ILLNESS.9
264	260		25-45-203. Drug manufacturers - authorized access to and use10
265	261		of individualized investigational drugs, biological products, or devices11
266	262		- costs. (1) A
267	263		MANUFACTURER OPERATING WITHIN AN ELIGIBLE FACILITY12
268	264		AND IN ACCORDANCE WITH APPLICABLE FEDERAL LAW MAY MAKE13
269	265		AVAILABLE TO AN ELIGIBLE PATIENT , AND AN ELIGIBLE PATIENT MAY14
270	266		REQUEST, THE MANUFACTURER 'S INDIVIDUALIZED INVESTIGATIONAL15
271	267		DRUG, BIOLOGICAL PRODUCT, OR DEVICE FROM THE ELIGIBLE FACILITY OR16
272	268		MANUFACTURER OPERATING WITHIN THE ELIGIBLE FACILITY .17
273	269		(2) A
274	270		MANUFACTURER OF AN INDIVIDUALIZED INVESTIGATIONAL18
275	271		DRUG, BIOLOGICAL PRODUCT, OR DEVICE MAY:19
276	272		(a) P
277	273		ROVIDE THE INDIVIDUALIZED INVESTIGATIONAL DRUG ,20
278	274		BIOLOGICAL PRODUCT, OR DEVICE TO AN ELIGIBLE PATIENT WITHOUT21
279	275		RECEIVING COMPENSATION; OR22
280	276		(b) R
281	277		EQUIRE AN ELIGIBLE PATIENT TO PAY THE COSTS OF, OR THE23
282	278		COSTS ASSOCIATED WITH, THE MANUFACTURE OF THE INDIVI DUALIZED24
283	279		INVESTIGATIONAL DRUG, BIOLOGICAL PRODUCT, OR DEVICE.25
284	280		(3) N
285	281		OTHING IN THIS PART 2 REQUIRES A MANUFACTURER OF AN26
286	282		INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR27
287	283		1270
288	284		-8- DEVICE TO MAKE THE INDIVIDUALIZED INVESTIGATIONAL DRUG ,1
289	285		BIOLOGICAL PRODUCT, OR DEVICE AVAILABLE TO AN ELIGIBLE PATIENT.2
290	286		(4) I
291	287		F A PATIENT DIES WHILE BEING TREATED WITH AN3
292	288		INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR4
293	289		DEVICE, THE PATIENT'S HEIRS ARE NOT LIABLE FOR OUTSTANDING DEBT5
294	290		RELATED TO THE TREATMENT, INCLUDING COSTS ATTRIBUTED TO LACK OF6
295	291		INSURANCE COVERAGE FOR THE TREATMENT .7
296	292		25-45-204. Action against health-care provider's license or8
297	293		medicare certification prohibited. N
298	294		OTWITHSTANDING ANY OTHER LAW ,9
299	295		A LICENSING BOARD SHALL NOT REVOKE , FAIL TO RENEW, SUSPEND, OR10
300	296		TAKE OTHER ACTION AGAINST A HEALTH -CARE PROVIDER'S LICENSE11
301	297		ISSUED PURSUANT TO TITLE 12 BASED SOLELY ON THE HEALTH -CARE12
302	298		PROVIDER'S RECOMMENDATION TO AN ELIGIBLE PATIENT REGARDING13
303	299		ACCESS TO OR TREATMENT WITH AN INDIVIDUALIZED INVESTIGATIONAL14
304	300		DRUG, BIOLOGICAL PRODUCT , OR DEVICE, SO LONG AS THE15
305	301		RECOMMENDATION IS CONSISTENT WITH MEDICAL STANDARDS OF CARE .16
306	302		A
307	303		CTION AGAINST A HEALTH-CARE PROVIDER'S MEDICARE CERTIFICATION17
308	304		BASED SOLELY ON THE HEALTH -CARE PROVIDER'S RECOMMENDATION18
309	305		THAT AN ELIGIBLE PATIENT HAVE ACCESS TO AN INDIVIDUALIZED19
310	306		INVESTIGATIONAL DRUG, BIOLOGICAL PRODUCT, OR DEVICE IS PROHIBITED.20
311	307		25-45-205. Access to individualized investigational drugs,21
312	308		biological products, and devices - prohibition on state action. A
313	309		N22
314	310		OFFICIAL, EMPLOYEE, OR AGENT OF THIS STATE SHALL NOT BLOCK OR23
315	311		ATTEMPT TO BLOCK AN ELIGIBLE PATIENT'S ACCESS TO AN INDIVIDUALIZED24
316	312		INVESTIGATIONAL DRUG, BIOLOGICAL PRODUCT, OR DEVICE. COUNSELING,25
317	313		ADVICE, OR A RECOMMENDATION CONSISTENT WITH MEDICAL ST ANDARDS26
318	314		OF CARE FROM A LICENSED HEALTH-CARE PROVIDER IS NOT A VIOLATION27
319	315		1270
320	316		-9- OF THIS SECTION.1
321	317		25-45-206. No cause of action created. T
322	318		HIS PART 2 DOES NOT2
323	319		CREATE A PRIVATE RIGHT OF ACTION AGAINST A MANUFACTURER OF AN3
324	320		INDIVIDUALIZED INVESTIGATIONAL DRUG , BIOLOGICAL PRODUCT, OR4
325	321		DEVICE, OR AGAINST AN INDIVIDUAL OR ENTITY INVOLVED IN THE CARE OF5
326	322		AN ELIGIBLE PATIENT USING AN INDIVIDUALIZED INVESTIGATIONAL DRUG ,6
327	323		BIOLOGICAL PRODUCT, OR DEVICE, FOR ANY HARM CAUSED TO THE7
328	324		ELIGIBLE PATIENT RESULTING FROM USE OF THE INDIVIDUALIZED8
329	325		INVESTIGATIONAL DRUG, BIOLOGICAL PRODUCT, OR DEVICE, SO LONG AS9
330	326		THE MANUFACTURER OR INDIVIDUAL OR ENTITY HAS MADE A GOOD FAITH10
331	327		EFFORT TO COMPLY WITH THE PROVISIONS OF THIS PART 2 AND HAS11
332	328		EXERCISED REASONABLE CARE IN ACTIONS TAKEN PURS UANT TO THIS PART12
333	329		2.13
334	330		25-45-207. Effect on health-care coverage. N
335	331		OTHING IN THIS14
336	332		PART 2 AFFECTS A HEALTH INSURANCE PROVIDER 'S OBLIGATION TO15
337	333		PROVIDE COVERAGE FOR AN INSURED 'S PARTICIPATION IN A CLINICAL16
338	334		TRIAL PURSUANT TO SECTION 10-16-104 (20).17
339	335		SECTION 6. Safety clause. The general assembly finds,18
340	336		determines, and declares that this act is necessary for the immediate19
341	337		preservation of the public peace, health, or safety or for appropriations for20
342	338		the support and maintenance of the departments of the state and state21
343	339		institutions.22
344	340		1270
345	341		-10-